PITTSBORO, NC--(Marketwire - March 12, 2008) - Biolex Therapeutics, Inc. today announced the publication of results of a Phase 1 clinical trial of Locteron®, a controlled-release interferon alfa in development for the treatment of chronic hepatitis C, in the Journal of Interferon & Cytokine Research. In the randomized Phase 1 trial, the administration of Locteron demonstrated bioactivity over a two-week period and resulted in flu-like side effects that were less frequent, milder and of a shorter duration than with PEG-Intron®, the standard of care used as the control arm in the trial. The Company also announced that updated results from its SELECT-1 Phase 2a trial of Locteron will be presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) conference April 23-27, 2008 in Milan, Italy.
